Rare disease drugmaker · based in San Diego, United States · founded 2011 · ticker TVTX · travere.com
Retrophin rebranded as Travere Therapeutics in November 2020 and is listed separately on Trial Friend. This legacy entry is maintained for historical reference. Sparrow Pharmaceuticals is a separate, independent company focused on cardiometabolic therapeutics and is not affiliated with Retrophin/Travere.
We did not find active Retrophin (now Travere Therapeutics) trials for the rare diseases we track on ClinicalTrials.gov right now.
More about Retrophin (now Travere Therapeutics)
The clinical trials section below shows active and recruiting rare disease studies sponsored by Retrophin (now Travere Therapeutics), sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites.
The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Retrophin (now Travere Therapeutics) is headquartered in San Diego, United States, founded in 2011, publicly traded under the ticker symbol TVTX. The company dedicates its research and development resources exclusively to rare and orphan diseases, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Retrophin (now Travere Therapeutics)'s own site is travere.com, and our help paying for treatment page lists drugmaker programs and charity funds.
Questions about Retrophin (now Travere Therapeutics)
Retrophin rebranded as Travere Therapeutics in November 2020 and is listed separately on Trial Friend. This legacy entry is maintained for historical reference. Sparrow Pharmaceuticals is a separate, independent company focused on cardiometabolic therapeutics and is not affiliated with Retrophin/Travere.
Yes. Retrophin (now Travere Therapeutics) is a rare disease specialist headquartered in San Diego, United States, founded in 2011. The company focuses primarily on developing treatments for rare and orphan diseases.
The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Retrophin (now Travere Therapeutics), pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.
To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.
None that we track as of November 2026. No Retrophin (now Travere Therapeutics) label in the FDA's openFDA database matches a rare disease on Trial Friend, which usually means the company has no approved product yet or its approved drugs are for common conditions.
In development: the trials list on this page shows what Retrophin (now Travere Therapeutics) is recruiting for now, and the FDA calendar lists any application once a decision date is public.
Retrophin (now Travere Therapeutics) was founded in 2011 and is headquartered in San Diego, United States. The company has been active for 15 years. It trades publicly under the ticker symbol TVTX. As a rare disease specialist, the company dedicates its resources to developing therapies for patients with rare and orphan conditions.